GLP1R and type 2 diabetes mellitus: The results of a meta-analysis from 2021 that included 76 placebo-controlled trials in which different GLP-1 RAs were used, and with a total number of 39,246 T2DM patients, clearly showed that GLP-1 RAs treatment for a period of at least 12 weeks significantly lowered HgbA1c, fasting glucose, and body weight.